Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Objective: To evaluate the effectiveness and safety of metformin use in clinical practice in a large sample of pharmacologically treated patients with type 2 diabetes and different levels of renal function. Design: Observational study between July 2004 and December 2010, mean follow-up 3.9 years. Setting: Hospital outpatient clinics and primary care in Sweden. Participants: 51 675 men and women with type 2 diabetes, registered in the Swedish National Diabetes Register, and on continuous glucose-lowering treatment with oral hypoglycaemic agents (OHAs) or insulin. Main outcome measures: Risks of cardiovascular disease (CVD), all-cause mortality and acidosis/serious infection, associated with each treatment regimens, were analysed in all patients and in subgroups with different estimated glomerular filtration rate (eGFR) intervals. Covariance adjustment and propensity scores were used to adjust for several baseline risk factors and characteristics at Cox regression. Results: Compared with metformin in monotherapy, HRs for fatal/non-fatal CVD and all-cause mortality with all other OHAs combined (approximately 80% sulphonylureas) in monotherapy were 1.02 (95% CI 0.93 to 1.12) and 1.13 (1.01 to 1.27), while 1.18 (1.07 to 1.29) and 1.34 (1.19 to 1.50) with insulin in monotherapy, adjusting using propensity scores. Metformin, compared with any other treatment, showed reduced risks of acidosis/serious infection (adjusted HR 0.85, 95% CI 0.74 to 0.97) and all-cause mortality (HR 0.87, 95% CI 0.77 to 0.99), in patients with eGFR 45–60 ml/min/1.73 m 2 , and no increased risks of all-cause mortality, acidosis/serious infection or CVD were found in patients with eGFR 30–45 ml/min/1.73 m 2 . Conclusions: Metformin showed lower risk than insulin for CVD and all-cause mortality and slightly lower risk for all-cause mortality compared with other OHA, in these 51 675 patients followed for 4 years. Patients with renal impairment showed no increased risk of CVD, all-cause mortality or acidosis/serious infection. In clinical practice, the benefits of metformin use clearly outbalance the risk of severe side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Concerns regarding lactic acidosis have not been substantiated.558,559”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [559]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“The UKPDS demonstrated a reduction in all-cause mortality in the subgroup of obese DM2 patients treated with metformin compared with diet, SU or insulin,(2) also confirmed in a 10-year post-interventional follow-up.(3) Furthermore, several recent observational studies have reported reduced risk with metformin compared…”
ResultProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“Additional checks of the form of the time dependence were made using plots of scaled Schoenfeld residuals.(27) All statistical analyses were performed with SAS V.”
MethodGlobal and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“INTRODUCTION Type 2 diabetes mellitus (DM2) is a common disease, which causes major morbidity and mortality due to micro- and macrovascular complications.(1) A range of glucose-lowering To cite: Ekström N, Schiöler L, Svensson A-M, et al.”
BackgroundCardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A. M., & Pajak, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,263
Cited by
Items 201–223 of 223
Use of Available Glucose-Lowering Agents in Patients with Different Levels of Renal Impairment
Garvey, W. T. (2013) · Endocrine Practice · doi:10.4158/ep12362.or
„Highlights“ des Diabetes Update 2013: Wichtige Studienergebnisse für den Diabetologen
Scherbaum, W. A. (2013) · Der Diabetologe · doi:10.1007/s11428-012-0977-z
Studies on the possible mechanisms behind the anti-diabetic effects of Xylitol.
Chukwuma, C. I. (2013) · ResearchSpace (University of KwaZulu-Natal)
Das geht an die Nieren! Schlechte Blutzuckereinstellung bei Diabetes mellitus
Drechsler, C. (2014) · Info Diabetologie · doi:10.1007/s15034-014-0621-7
METODENS STRINGENS OCH RESULTATETS RELEVANS: RCTer och registerstudier som stöd i kliniskt arbete
Svensson, K. (2016) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Usage of metformin in patients with type 2 diabetes mellitus
Huang, W. (2016) · UTAS Research Repository · doi:10.25959/23240615
Fall 71: Spätschäden – 49 Jahre, ♀, DM Typ 2, Progression der Niereninsuffizienz
Kihm, L. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_71
The role of metformin in the prevention of diabetic nephropathy in experimental type 2 diabetes
Bayrasheva, V. K., Babenko, A. Y., Dmitriev, Y. V., Bairamov, A. A., Чефу, С. Г., Shatalov, I. S., Arefieva, A. N., Pchelin, I. Y., Hudiakova, N. V., Aliev, P., et al. (2016) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2016-15-3-70-80
Continuation or termination of metformin in diabetic patients exposed to iodinated contrast medium?
Dayani, M. A. (2019) · Journal of Renal Injury Prevention · doi:10.15171/jrip.2019.34
The impact of metformin in chronic kidney disease-mineral and bone disorder
Masumi, R., Tolouian, R., Tolouian, A., & Mohmoodnia, L. (2020) · Journal of Nephropharmacology · doi:10.34172/npj.2021.02
Das geht an die Nieren! Schlechte Blutzuckereinstellung bei Diabetes mellitus
Drechsler, C., Schneider, A., Schmidt, K.-R., & Wanner, C. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-2867-3
Qureshi, R., Nasir, K., Dhrolia, M. F., & Ahmad, A. (2022) · Cureus · doi:10.7759/cureus.21291
COVID-19: Can Metformin Drastically Reduce the Number of Deaths?
Lorenzo, B. (2021) · Journal of Medical - Clinical Research & Reviews · doi:10.33425/2639-944x.1186
Evre 4 ve 5 Kronik Böbrek Hastaları Metformin Kullanmamalı mı?
Çiftçioğlu, M. (2022) · Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi · doi:10.17517/ksutfd.1181458
Li, Y., Dong, L., Huang, H., Zhou, Y., Yin, Q., Wu, X., Du, Z., Han, L., Wu, J., Wu, L., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4214516/v1
Liu, P., Pan, Y., Song, Y., Zhou, Y., Zhang, W., Li, X., Li, J., Li, Y., & Ma, L. (2024) · Figshare · doi:10.6084/m9.figshare.26565935
Perspective Chapter: Metformin and its Role in Diabetic Kidney Disease and Glucose Control
Kulkarni, A., & Syeda, S. (2026) · Pharmaceutical science. · doi:10.5772/intechopen.1011446
Metformin & Chronic Kidney Disease (CKD) : a reassessment of the benefit/risk ratio
Kajbaf, F. (2015) · theses.fr (ABES) · doi:10.70675/7a26b581z94ddz4e2fz9a48z97f6f7d8354a
Response to “Moving forward from Cockcroft-Gault creatinine clearance”
Ariano, R. E., Zelenitsky, S. A., Davis, C., & McCormack, J. P. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag341
Peter, W. L. S., Bzowyckyj, A. S., & Pai, M. P. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag343
Borrego-Moreno, J. C., Adame-Moreira, A., Rivas-Santiago, B. T., & Serrano, C. J. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1994_25
Metadata
- Authors
- Ekström, N., Schiöler, L., Svensson, A.-M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B., Cederholm, J., Eliasson, B., & Gudbjörnsdottir, S.
- Affiliations
- University of Gothenburg (SE)
- Region Västra Götaland (SE)
- Department of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Centre of Registers in Region Västra Götaland, Gothenburg, Sweden
- Uppsala University (SE)
- Corresponding author
- Ekström, Nils
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2012
- Volume
- 2
- Issue
- 4
- Pages
- e001076
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3400073
- OpenAlex
- W2167639134
- Cited by
- 221
- References
- 39
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 24 · 2020: 19 · 2019: 19 · 2018: 13 · 2017: 26 · 2016: 18 · 2015: 18 · 2014: 29 · 2013: 13
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Sveriges Kommuner och Landsting
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, type 2 diabetes, renal function, estimated glomerular filtration rate, cardiovascular disease, all-cause mortality, lactic acidosis, serious infections, sulfonylureas, insulin monotherapy, oral antidiabetic drugs, drug safety, treatment effectiveness, Swedish National Diabetes Register, propensity score adjustment, real-world clinical practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
